Interesting - In the abstract you have linked to that is combined with all the others, there is more 'color' to the data:
In the secondary outcome endpoints preliminary analysis of data from subjects to date shows an average improvement of the MMSE score at week 12 in PART B (week 17 from baseline). A significant majority of all patients tested so far improved their respective MMSE score. The average EEG/ERP (P300 amplitude) signal also improved and also the average Cogstate test improved across the test batteries. Conclusions: Data collected so far indicate that ANAVEX 2-73 is safe and well tolerated. Interim results also show improved cognitive performance after drug administration in subjects with mild-to-moderate AD.